IT1254995B - Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani - Google Patents

Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani

Info

Publication number
IT1254995B
IT1254995B ITMI921556A ITMI921556A IT1254995B IT 1254995 B IT1254995 B IT 1254995B IT MI921556 A ITMI921556 A IT MI921556A IT MI921556 A ITMI921556 A IT MI921556A IT 1254995 B IT1254995 B IT 1254995B
Authority
IT
Italy
Prior art keywords
agonists
pathologies
rhythms
circandian
interfer
Prior art date
Application number
ITMI921556A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ITMI921556A priority Critical patent/IT1254995B/it
Publication of ITMI921556A0 publication Critical patent/ITMI921556A0/it
Priority to EP93830270A priority patent/EP0578620B1/en
Priority to JP5152525A priority patent/JPH0672874A/ja
Priority to AT93830270T priority patent/ATE200617T1/de
Priority to DE69330150T priority patent/DE69330150D1/de
Publication of ITMI921556A1 publication Critical patent/ITMI921556A1/it
Priority to US08/196,380 priority patent/US5552428A/en
Application granted granted Critical
Publication of IT1254995B publication Critical patent/IT1254995B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Il presente trovato ha come oggetto un farmaco, il quale prevede la somministrazione della melatonina e/o suoi agonisti, particolarmente nelle patologia che inteferiscono con i ritmi circadiani, la quale presenta la peculiarità di essere utilizzata in via transdermica, mediante l'applicazione di composti, che comprendono nella formulazione base, melatonina o suoi agonisti, in una percentuale compresa tra lo 0,1 ed il 5%.
ITMI921556A 1992-06-24 1992-06-24 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani IT1254995B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI921556A IT1254995B (it) 1992-06-24 1992-06-24 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
EP93830270A EP0578620B1 (en) 1992-06-24 1993-06-24 Pharmaceutical compositions for transdermal delivery of melatonin and/or its analogues
JP5152525A JPH0672874A (ja) 1992-06-24 1993-06-24 概日リズム障害疾患用薬剤
AT93830270T ATE200617T1 (de) 1992-06-24 1993-06-24 Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
DE69330150T DE69330150D1 (de) 1992-06-24 1993-06-24 Pharmazeutische Zusammensetzungen zur transdermalen Verabreichung von Melatonin und/oder seine Analoge
US08/196,380 US5552428A (en) 1992-06-24 1994-02-15 Compounds effective in the treatment of circadian rhythms and related disorders, the novel pharmaceutical preparations and novel method of application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI921556A IT1254995B (it) 1992-06-24 1992-06-24 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani

Publications (3)

Publication Number Publication Date
ITMI921556A0 ITMI921556A0 (it) 1992-06-24
ITMI921556A1 ITMI921556A1 (it) 1993-12-24
IT1254995B true IT1254995B (it) 1995-10-11

Family

ID=11363575

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI921556A IT1254995B (it) 1992-06-24 1992-06-24 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani

Country Status (5)

Country Link
EP (1) EP0578620B1 (it)
JP (1) JPH0672874A (it)
AT (1) ATE200617T1 (it)
DE (1) DE69330150D1 (it)
IT (1) IT1254995B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5958683A (en) * 1994-03-30 1999-09-28 Novartis Corporation Screening method using the RZR receptor family
DE19713141A1 (de) * 1996-03-29 1997-10-30 Labtec Gmbh Transdermales System mit Melatonin
FR2754454B1 (fr) * 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
IT1289939B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
AU6595100A (en) 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
EP1206943B1 (en) 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Matrix adhering to nasal mucosa
US7884037B2 (en) 2006-12-15 2011-02-08 Kimberly-Clark Worldwide, Inc. Wet wipe having a stratified wetting composition therein and process for preparing same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
DE3685696T2 (de) * 1985-03-04 1993-01-14 Cell Eng Ag Melatoninhaltige mittel sowie deren verwendungen.
JPS61212512A (ja) * 1985-03-19 1986-09-20 Shiseido Co Ltd 養毛料
JPS61221106A (ja) * 1985-03-28 1986-10-01 Shiseido Co Ltd 皮膚外用剤
GB8517958D0 (en) * 1985-07-16 1985-08-21 Cellena Cell Eng Ag Compositions containing melatonin/homologues
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
DK0483077T3 (da) * 1990-09-28 1996-04-15 I F L O S A S Di Giorgio E Ald Fremgangsmåde til syntese af et kontraceptivt og menstruationscyklus-kontrollerende lægemiddel med onkostatiske, antikinetosiske, præventive og terapeutiske egenskaber til behandling af brysttumorer og melanomer
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin

Also Published As

Publication number Publication date
EP0578620B1 (en) 2001-04-18
EP0578620A1 (en) 1994-01-12
DE69330150D1 (de) 2001-05-23
ITMI921556A1 (it) 1993-12-24
ITMI921556A0 (it) 1992-06-24
ATE200617T1 (de) 2001-05-15
JPH0672874A (ja) 1994-03-15

Similar Documents

Publication Publication Date Title
JO1502B1 (en) New pharmacy vehicles
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
DE69317139D1 (de) Retinoid enthaltende, wässrige, gelartige Darreichungsform
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
IT1254995B (it) Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IE873125L (en) Benzimidazole derivatives
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
SE8404065D0 (sv) Novel biologically active compounds
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
IT8468281A1 (it) Proglumide e composizioni farmaceutiche che la contengono per l'impiego nella terapia di affezioni neoplastiche.
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
IT8521322A0 (it) Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
PT1202956E (pt) Derivados terapeuticos e/ou nuricionalmente melhorados de ingredientes activos e composicoes de administracao oral contendo o mesmo
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
DE69910787D1 (de) Neuartige, pharmazeutisch aktive verbindung
ITRM910155A0 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi.
IT1244647B (it) Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.
IT1190194B (it) Combinazione di analgesico centrale ed adenina per il trattamento analgesico del corpo umano o animale e composizione farmaceutica che la contiene
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
FR2567755B1 (fr) Nouveau medicament anti-tumoral contenant comme ingredient actif le triacetoxy-1,8,9 anthracene
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
RU94033096A (ru) Соединение, способ лечения и фармацевтическая композиция

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970624